Stemline Therapeutics (STML) Stock Rating Upgraded by BidaskClub

BidaskClub upgraded shares of Stemline Therapeutics (NASDAQ:STML) from a hold rating to a buy rating in a report issued on Saturday morning, BidAskClub reports.

A number of other analysts have also recently weighed in on the stock. Piper Jaffray Companies raised their price target on shares of Stemline Therapeutics to $30.00 and gave the company an overweight rating in a report on Wednesday, December 26th. Roth Capital set a $33.00 price target on shares of Stemline Therapeutics and gave the company a buy rating in a report on Sunday, December 23rd. ValuEngine cut shares of Stemline Therapeutics from a buy rating to a hold rating in a report on Thursday, January 3rd. Finally, HC Wainwright reiterated a buy rating and issued a $38.00 target price on shares of Stemline Therapeutics in a research note on Wednesday, December 26th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Stemline Therapeutics currently has an average rating of Buy and an average target price of $26.00.

NASDAQ:STML opened at $13.99 on Friday. Stemline Therapeutics has a fifty-two week low of $7.82 and a fifty-two week high of $20.55. The stock has a market capitalization of $626.10 million, a PE ratio of -4.68 and a beta of 1.14.



In other Stemline Therapeutics news, CAO David Gionco sold 13,492 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $11.11, for a total transaction of $149,896.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Kenneth Hoberman sold 10,557 shares of the firm’s stock in a transaction that occurred on Monday, February 25th. The stock was sold at an average price of $12.05, for a total transaction of $127,211.85. The disclosure for this sale can be found here. Insiders sold a total of 180,999 shares of company stock valued at $2,048,415 over the last quarter. 14.80% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently bought and sold shares of the business. Great West Life Assurance Co. Can purchased a new position in Stemline Therapeutics during the 4th quarter worth approximately $47,000. Legal & General Group Plc raised its position in Stemline Therapeutics by 27.1% during the 4th quarter. Legal & General Group Plc now owns 5,249 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 1,120 shares during the last quarter. Metropolitan Life Insurance Co. NY raised its position in Stemline Therapeutics by 327.0% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 8,523 shares of the biopharmaceutical company’s stock worth $81,000 after buying an additional 6,527 shares during the last quarter. Bank of America Corp DE raised its position in Stemline Therapeutics by 56.8% during the 4th quarter. Bank of America Corp DE now owns 10,669 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 3,866 shares during the last quarter. Finally, Janney Montgomery Scott LLC purchased a new position in Stemline Therapeutics during the 4th quarter worth approximately $108,000. 47.32% of the stock is owned by institutional investors.

About Stemline Therapeutics

Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.

Read More: Portfolio Manager

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.